In vitro activity of voriconazole against Candida species

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 1, 1998, Pages 297-300

  Kauffman, Carol A ^a   Zarins, Lidija T ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; DRUG EVALUATION, PRECLINICAL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 0031900016     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00005-4     Document Type: Article

References (17)

1. Barchiesi F, Restrepo D, McGough A, Rinaldi MG. In vitro activity of a new antifungal triazole: UK-109,496, abstract F71. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995;125 American Society for Microbiology, Washington, DC.
2. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother. 40:1996;1948-1949.
3. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother. 41:1997;1840-1842.
4. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 38:1994;2495-2497.
5. Hitchcock CA, Pye GW, Oliver GP, Troke PF. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections antifungal activity and selectivity in vitro, abstract F72 . Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995;125 American Society for Microbiology, Washington, DC.
6. Jones PG, Kauffman CA, McAuliffe MS, Liepman MK, Bergman AG. Efficacy of ketoconazole versus nystatin for the prevention of fungal infections in neutropenic patients. Arch Intern Med. 144:1984;549-551.
7. Kauffman CA, Liepman MK, Bergman AG, Mioduszewski J. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients reduction of infection and effect on bacterial and fungal flora . Am J Med. 74:1983;599-607.
8. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother. 41:1997;1832-1834.
9. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK 109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 41:1997;696-698.
10. Reference method for broth dilution antifungal susceptibility testing of yeasts tentative standard M27-T . 1995;NCCLS, Villanova, PA.
11. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 38:1994;1422-1424.
12. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 41:1997;841-843.
13. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 41:1997;575-577.
14. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother. 41:1997;2492-2496.
15. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, Kauffman CA. Epidemiology of oral candidiasis in HIV infected patients colonization, infection, treatment, and emergence of fluconazole resistance . Am J Med. 97:1994;339-347.
16. Tiballi RN, Zarins LT, He X, Kauffman CA. Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays. J Clin Microbiol. 33:1995;2612-2615.
17. Troke PF, Bell AS, Dickinson RP, Hitchcock CA, Jezequel S, Narayanaswami S, Ray SJ, Richardson K. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections discovery and antifungal properties, abstract F70 . Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995;125 American Society for Microbiology, Washington, DC.